Pharmaessentia Corporation

Myelopro Diagnostics and Research Gmbh

Oleh Zagrijtschuk

Ko-Chung Lin

Christoph Klade

Ruochen Jia

The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferative neoplasms or myelodysplasia syndrome. The present invention also relates to screening assays allowing the identification of such compounds.

Compounds targeting mutant calreticulin

Described is a method for treating an infectious disease, cancer, or myeloproliferative disease in a subject, wherein a 50 to 540 μg dose of a pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Dosage regimen for pegylated interferon

A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 &#x3bc;g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Growing community of inventors

Vienna, Austria

Oleh Zagrijtschuk